The final results of the tender process to allow domestic cultivation has been announced by the German Federal Institute for Drugs and Medical Devices (BfArM), confirming the preliminary results that we reported last month. The applicant who challenged some of the assigned lots was unsuccessful. Aurora's German subsidiary, Aurora Produktions GmbH was awarded five lots, as well as Aphira Deutschland GmbH. Demecan, Wayland's German subsidiary, was awarded with three lots.
Now, the three companies have 18 months of time to deliver the first batch of products, which must comply with GACP and GMP standards.
The agreed production for the 13 lots consists of 10,400 kg over four years, with each lot being of 200 kg per year.